Synergy Spine Solutions Reports Two-Year Synergy Disc Outcomes
Miami, Florida, USA, September 16, 2026 Synergy Spine Solutions® has highlighted new two-year clinical outcomes for its FDA-approved Synergy...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Miami, Florida, USA, September 16, 2026 Synergy Spine Solutions® has highlighted new two-year clinical outcomes for its FDA-approved Synergy...
Fruita, Colorado, August 12, 2026 Neuralytix, LLC announced the full commercial availability of its iD3 System, an FDA 510(k)-cleared...
MONTEREY, Calif., July 29, 2026 Elevation Spine has received U.S. Food and Drug Administration (FDA) 510(k) Clearance for Saber-C®...
BOCA RATON, Fla., June 2026 SurGenTec® has announced U.S. FDA clearance for its ION-L™ Lumbar Facet Fixation System, a...
